The inventive subject matter provides compositions and methods for treating fibrosis of the liver and reducing extracellular matrix proteins in the liver. Preferred compositions will include a set of active compounds consisting essentially of two or more isolated and purified monosaccharides selected from galacturonic acid, galactose, arabinose, rhamnose, glucose, xylose, and mannose.